NASDAQ:GRTS - Gritstone Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gritstone Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.45 +0.05 (+0.48 %) (As of 02/23/2020 08:28 AM ET) Add Compare Today's Range$10.02Now: $10.45▼$10.5250-Day Range$7.76MA: $9.47▼$11.3152-Week Range$7.00Now: $10.45▼$15.94Volume61,980 shsAverage Volume101,362 shsMarket Capitalization$374.21 millionP/E RatioN/ADividend YieldN/ABeta1.18 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRTS Previous Symbol CUSIPN/A CIKN/A Webhttp://www.gritstoneoncology.com/ Phone510-871-6100Debt Debt-to-Equity Ratio0.12 Current Ratio6.76 Quick Ratio6.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.19 million Price / Sales314.47 Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book2.03Profitability EPS (Most Recent Fiscal Year)($7.26) Net Income$-64,780,000.00 Net Margins-1,838.71% Return on Equity-54.23% Return on Assets-41.94%Miscellaneous Employees113 Outstanding Shares35,810,000Market Cap$374.21 million Next Earnings Date3/26/2020 (Estimated) OptionableNot Optionable Receive GRTS News and Ratings via Email Sign-up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GRTS Rates by TradingView Gritstone Oncology (NASDAQ:GRTS) Frequently Asked Questions What is Gritstone Oncology's stock symbol? Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS." How were Gritstone Oncology's earnings last quarter? Gritstone Oncology Inc (NASDAQ:GRTS) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.11. The company earned $0.98 million during the quarter, compared to analysts' expectations of $1.20 million. Gritstone Oncology had a negative return on equity of 54.23% and a negative net margin of 1,838.71%. View Gritstone Oncology's Earnings History. When is Gritstone Oncology's next earnings date? Gritstone Oncology is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Gritstone Oncology. What price target have analysts set for GRTS? 5 analysts have issued 1-year price targets for Gritstone Oncology's shares. Their forecasts range from $17.00 to $20.00. On average, they anticipate Gritstone Oncology's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price. View Analyst Price Targets for Gritstone Oncology. What is the consensus analysts' recommendation for Gritstone Oncology? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gritstone Oncology. What are Wall Street analysts saying about Gritstone Oncology stock? Here are some recent quotes from research analysts about Gritstone Oncology stock: 1. According to Zacks Investment Research, "Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patients tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients TSNA to drive the patients immune system to attack and destroy tumors. " (10/15/2019) 2. HC Wainwright analysts commented, "We maintain our Buy rating of GRTS and our 12-month price target of $17.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected GRANITE-001 and SLATE-001 revenues through 2030, assuming a 12.5% discount rate and 3% terminal growth rate." (4/1/2019) Has Gritstone Oncology been receiving favorable news coverage? News stories about GRTS stock have been trending very negative recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gritstone Oncology earned a news sentiment score of -3.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Gritstone Oncology. Are investors shorting Gritstone Oncology? Gritstone Oncology saw a increase in short interest in January. As of January 31st, there was short interest totalling 3,410,000 shares, an increase of 14.0% from the January 15th total of 2,990,000 shares. Based on an average daily volume of 173,200 shares, the short-interest ratio is presently 19.7 days. Approximately 17.5% of the shares of the stock are sold short. View Gritstone Oncology's Current Options Chain. Who are some of Gritstone Oncology's key competitors? Some companies that are related to Gritstone Oncology include SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Beam Therapeutics (BEAM), I-Mab (BDTX), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX), BAVARIAN NORDIC/S (BVNRY), Twist Bioscience (TWST), Krystal Biotech (KRYS), Adverum Biotechnologies (ADVM), Mesoblast (MESO), Aerie Pharmaceuticals (AERI), Sangamo Therapeutics (SGMO), DBV TECHNOLOGIE/S (DBVT) and Vericel (VCEL). What other stocks do shareholders of Gritstone Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone Oncology investors own include Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), AT&T (T), Agile Therapeutics (AGRX), Micron Technology (MU), Nektar Therapeutics (NKTR), Proteostasis Therapeutics (PTI), vTv Therapeutics (VTVT) and AbbVie (ABBV). Who are Gritstone Oncology's key executives? Gritstone Oncology's management team includes the folowing people: Dr. Andrew R. Allen, Co-Founder, Pres, CEO & Director (Age 52)Dr. Karin Jooss, Exec. VP of Research & Chief Scientific Officer (Age 54)Prof. Raphaël F. Rousseau M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 50)Mr. Jean-Marc Bellemin M.B.A., Exec. VP of Fin. & CFO (Age 47)Dr. Roman Yelensky, Exec. VP & CTO (Age 40) When did Gritstone Oncology IPO? (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager. Who are Gritstone Oncology's major shareholders? Gritstone Oncology's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Casdin Capital LLC (6.03%), State Street Corp (1.31%), UBS Asset Management Americas Inc. (1.08%), Victory Capital Management Inc. (1.03%) and Victory Capital Management Inc. (1.02%). Company insiders that own Gritstone Oncology stock include Nicholas Simon and Raphael Rousseau. View Institutional Ownership Trends for Gritstone Oncology. Which institutional investors are selling Gritstone Oncology stock? GRTS stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Oxford Asset Management LLP, Victory Capital Management Inc., Victory Capital Management Inc., New York State Common Retirement Fund and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Gritstone Oncology. Which institutional investors are buying Gritstone Oncology stock? GRTS stock was purchased by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Captrust Financial Advisors, State Street Corp, California Public Employees Retirement System, Geode Capital Management LLC, Goldman Sachs Group Inc., Barclays PLC and ProShare Advisors LLC. View Insider Buying and Selling for Gritstone Oncology. How do I buy shares of Gritstone Oncology? Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Gritstone Oncology's stock price today? One share of GRTS stock can currently be purchased for approximately $10.45. How big of a company is Gritstone Oncology? Gritstone Oncology has a market capitalization of $374.21 million and generates $1.19 million in revenue each year. The company earns $-64,780,000.00 in net income (profit) each year or ($7.26) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe.View Additional Information About Gritstone Oncology. What is Gritstone Oncology's official website? The official website for Gritstone Oncology is http://www.gritstoneoncology.com/. How can I contact Gritstone Oncology? Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at [email protected] MarketBeat Community Rating for Gritstone Oncology (NASDAQ GRTS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 98 (Vote Outperform)Underperform Votes: 85 (Vote Underperform)Total Votes: 183MarketBeat's community ratings are surveys of what our community members think about Gritstone Oncology and other stocks. Vote "Outperform" if you believe GRTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRTS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2020 by MarketBeat.com StaffFeatured Article: What is Cost of Goods Sold (COGS)?
